We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , Bio-Techne Corporation (TECH - Free Report) , Exelixis, Inc. (EXEL - Free Report) , Paratek Pharmaceuticals, Inc. and Bioverativ .
Here are highlights from Tuesday’s Analyst Blog:
Fancy Biotech Picks on Buyout Buzz? 5 Top Picks
Biotech stocks have been moving north of late, largely driven by a spate of deal news. Such deals lend financial stability to businesses and maximize shareholders’ wealth. Further, more deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Corporate taxes, in the meantime, will be trimmed and price gouging fears have ebbed, which bode well for biotech companies. Banking on such positives, investing in sound biotech stocks seems judicious.
Biotech ETFs Hit Record High on Deal News
The biotech sector scaled record highs on Jan 22 following a couple of multi-dollar deals. After all, a flurry of mergers in any sector is always encouraging. Such mergers give control over the markets, increase value and reduce costs. Needless to say, these also lead to economy of scale through sharing of resources, reduced risks owing to usage of innovative techniques as well as tax advantage.
The SPDR S&P Biotech ETF (XBI) rose 3.8%, the biggest one-day percentage gain since June 2017. The fund registered a gain of 9% so far this year, well above the 5.4% rise of the S&P 500. For quite some time, the fund has remained popular among investors and has seen inflows of $216.2 million on a year-to-date basis. On the other hand, the fund has witnessed a meager outflow of $35.9 million during the same period, per FactSet. Similarly, the iShares Nasdaq Biotechnology ETF (IBB) went up 2.6% to $114.9, the highest since September 2015. The fund also posted its biggest one-day percentage gain since last August.
The rise followed Sanofi’s acquisition of Bioverativ for $11.6 billion in order to establish its authority in the specialty care space. The French company insisted on paying $105 in cash for each share purchased. This represents a whopping 64% premium to Bioverativ’s closing price on Jan 19, according to Sanofi. Even though Sanofi’s shares took a beating, the company expects the deal to boost earnings in 2018 and help it achieve return on invested capital in just about three years. Shares of Bioverativ, in the meantime, jumped 61.9% to close at $103.79. In fact, the company saw its share price hit an intraday high of $104.30 (read more: Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips).
Another biotech buyout hogging the limelight is that of Juno Therapeutics and Celgene. The latter agreed to buy Juno Therapeutics for $9 billion, or $87 a cash. This deal will help Celgene access the Seattle-based firm’s CAR-T cancer drug pipeline. Celgene added that Juno's research capabilities will strengthen the company’s leadership in hematology and add new drivers for growth in the long run. The deal is expected to add 50 cents per share to Celgene’s adjusted earnings this year. Shares of both Celgene and Juno Therapeutics were up 0.3% and 26.8%, respectively (read more: Juno Hits 52-Week High on Celgene's Rumored Buyout Interest).
Mergers to Gain Momentum, Tax Plan to Boost Profits
Courtesy of the new tax overhaul policy, biotech firms are able to repatriate hundreds of billions of dollars stranded overseas and pay only 8% to 15.5% tax, instead of the current 35%. This extra cash can be used for merger and acquisition activities. Biotech firms have around $500 billion in cash to invest in merger and acquisitions, while Jay Rao, a medical doctor and money manager at Balyasny Asset Management had said that “M&A and consolidation are inevitable” in the biotech sector.
President Trump’s business tax plan should also benefit biotech companies. The headline-grabbing corporate tax rate will be lowered from 35% to 21% and will be implemented this year, instead of being delayed until 2019. The lower tax burden is expected to boost profits for large biotech companies (read more: GOP Passes Landmark Tax Bill: Best & Worst for Stocks).
5 Best Biotech Stocks to Buy Now
The biotech sector has come alive, courtesy of a slew of deals. Notably, such deals can further get a boost from the new U.S. tax reform. Inventors have also, lately, started to feel that drug pricing issues won’t be as damaging as feared. Earlier, fears that price control could be put in place had deterred investors from investing in biotech.
Given the positives, it seems prudent to invest in five solid biotech firms. Such stocks essentially have strong fundamentals, thus being great investment options. Also, these companies flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy).
Anthera Pharmaceuticals, Inc. focuses on the development and commercialization of medicines for patients with unmet medical needs. The biopharmaceutical company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings surged more than 100% over the last 90 days. The company’s expected growth rate for the current year is 76%, higher than the Zacks Medical - Biomedical and Genetics industry’s rally of 6.2%.
Bio-Techne Corporation together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls. The company carries a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings advanced 1.3% over the last 90 days. The company’s expected growth rate for the current year is 8.9%, higher than the industry’s rally of 6.2%.
Exelixis, Inc. — a Zacks Rank #1 biopharmaceutical company — engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for cancer patients. The Zacks Consensus Estimate for its current-year earnings soared 88.5% over the last 90 days. The company’s expected growth rate for the current year is 313%, way higher than the industry’s rally of 6.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based on tetracycline chemistry in the United States. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings climbed more than 100% over the last 90 days. The company’s expected growth rate for the current year is 39.8%, higher than the industry’s gain of 6.2%.
Bioverativ focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders. This company has a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings increased 8.5% over the last 90 days. The company’s expected growth rate for the next quarter is a solid 39.7%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
For Immediate Release
Chicago, IL – January 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , Bio-Techne Corporation (TECH - Free Report) , Exelixis, Inc. (EXEL - Free Report) , Paratek Pharmaceuticals, Inc. and Bioverativ .
Here are highlights from Tuesday’s Analyst Blog:
Fancy Biotech Picks on Buyout Buzz? 5 Top Picks
Biotech stocks have been moving north of late, largely driven by a spate of deal news. Such deals lend financial stability to businesses and maximize shareholders’ wealth. Further, more deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Corporate taxes, in the meantime, will be trimmed and price gouging fears have ebbed, which bode well for biotech companies. Banking on such positives, investing in sound biotech stocks seems judicious.
Biotech ETFs Hit Record High on Deal News
The biotech sector scaled record highs on Jan 22 following a couple of multi-dollar deals. After all, a flurry of mergers in any sector is always encouraging. Such mergers give control over the markets, increase value and reduce costs. Needless to say, these also lead to economy of scale through sharing of resources, reduced risks owing to usage of innovative techniques as well as tax advantage.
The SPDR S&P Biotech ETF (XBI) rose 3.8%, the biggest one-day percentage gain since June 2017. The fund registered a gain of 9% so far this year, well above the 5.4% rise of the S&P 500. For quite some time, the fund has remained popular among investors and has seen inflows of $216.2 million on a year-to-date basis. On the other hand, the fund has witnessed a meager outflow of $35.9 million during the same period, per FactSet. Similarly, the iShares Nasdaq Biotechnology ETF (IBB) went up 2.6% to $114.9, the highest since September 2015. The fund also posted its biggest one-day percentage gain since last August.
The rise followed Sanofi’s acquisition of Bioverativ for $11.6 billion in order to establish its authority in the specialty care space. The French company insisted on paying $105 in cash for each share purchased. This represents a whopping 64% premium to Bioverativ’s closing price on Jan 19, according to Sanofi. Even though Sanofi’s shares took a beating, the company expects the deal to boost earnings in 2018 and help it achieve return on invested capital in just about three years. Shares of Bioverativ, in the meantime, jumped 61.9% to close at $103.79. In fact, the company saw its share price hit an intraday high of $104.30 (read more: Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips).
Another biotech buyout hogging the limelight is that of Juno Therapeutics and Celgene. The latter agreed to buy Juno Therapeutics for $9 billion, or $87 a cash. This deal will help Celgene access the Seattle-based firm’s CAR-T cancer drug pipeline. Celgene added that Juno's research capabilities will strengthen the company’s leadership in hematology and add new drivers for growth in the long run. The deal is expected to add 50 cents per share to Celgene’s adjusted earnings this year. Shares of both Celgene and Juno Therapeutics were up 0.3% and 26.8%, respectively (read more: Juno Hits 52-Week High on Celgene's Rumored Buyout Interest).
Mergers to Gain Momentum, Tax Plan to Boost Profits
Courtesy of the new tax overhaul policy, biotech firms are able to repatriate hundreds of billions of dollars stranded overseas and pay only 8% to 15.5% tax, instead of the current 35%. This extra cash can be used for merger and acquisition activities. Biotech firms have around $500 billion in cash to invest in merger and acquisitions, while Jay Rao, a medical doctor and money manager at Balyasny Asset Management had said that “M&A and consolidation are inevitable” in the biotech sector.
President Trump’s business tax plan should also benefit biotech companies. The headline-grabbing corporate tax rate will be lowered from 35% to 21% and will be implemented this year, instead of being delayed until 2019. The lower tax burden is expected to boost profits for large biotech companies (read more: GOP Passes Landmark Tax Bill: Best & Worst for Stocks).
5 Best Biotech Stocks to Buy Now
The biotech sector has come alive, courtesy of a slew of deals. Notably, such deals can further get a boost from the new U.S. tax reform. Inventors have also, lately, started to feel that drug pricing issues won’t be as damaging as feared. Earlier, fears that price control could be put in place had deterred investors from investing in biotech.
Given the positives, it seems prudent to invest in five solid biotech firms. Such stocks essentially have strong fundamentals, thus being great investment options. Also, these companies flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy).
Anthera Pharmaceuticals, Inc. focuses on the development and commercialization of medicines for patients with unmet medical needs. The biopharmaceutical company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings surged more than 100% over the last 90 days. The company’s expected growth rate for the current year is 76%, higher than the Zacks Medical - Biomedical and Genetics industry’s rally of 6.2%.
Bio-Techne Corporation together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls. The company carries a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings advanced 1.3% over the last 90 days. The company’s expected growth rate for the current year is 8.9%, higher than the industry’s rally of 6.2%.
Exelixis, Inc. — a Zacks Rank #1 biopharmaceutical company — engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for cancer patients. The Zacks Consensus Estimate for its current-year earnings soared 88.5% over the last 90 days. The company’s expected growth rate for the current year is 313%, way higher than the industry’s rally of 6.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based on tetracycline chemistry in the United States. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings climbed more than 100% over the last 90 days. The company’s expected growth rate for the current year is 39.8%, higher than the industry’s gain of 6.2%.
Bioverativ focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders. This company has a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings increased 8.5% over the last 90 days. The company’s expected growth rate for the next quarter is a solid 39.7%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.